Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program
RUA GOLD Expands High-Grade Intercepts at Depth at Auld Creek: 5.9g/t AuEq over 9m and 48.3g/t AuEq over 1.25m
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis